Friday, September 14, 2012

JNJ - Tuberculosis drug TMC027 gets priority review from USFDA

Janssen R&D, LLC, a subsidiary of Johnson & Johnson, has received priority review to the new drug application, or NDA, from FDA for bedaquiline, or TMC207, to treat pulmonary, multi-drug resistant tuberculosis, or MDR-TB, in adults as part of combination therapy

No comments:

Post a Comment